The company is not selling any shares of common stock under this prospectus and will not receive any proceeds from the sale by the selling stockholder of such shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBRX:
- Moleculin, CNS, Global-e, Tenet, Summit: Trending by Analysts
- Moleculin Biotech’s Promising Earnings Call Highlights
- Moleculin Biotech upgraded to Buy from Hold at Maxim
- Moleculin Biotech Advances Clinical Trials Amid Financial Losses
- Promising Advancements in Moleculin Biotech’s Annamycin Pivotal Trial Drive Buy Rating and $8 Price Target